Shulman, David SWhittle, Sarah BSurdez, DidierBailey, Kelly Mde-Alava, EnriqueYustein, Jason TShlien, AdamHayashi, MasanoriBishop, Alexander J RCrompton, Brian DDuBois, Steven GShukla, NeeravLeavey, Patrick JLessnick, Stephen LKovar, HeinrichDelattre, OlivierGrünewald, Thomas G PAntonescu, Cristina RRoberts, Ryan DToretsky, Jeffrey ATirode, FranckGorlick, RichardJaneway, Katherine AReed, DamonLawlor, Elizabeth RGrohar, Patrick J2023-05-032023-05-032022-09-17Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, et al. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17;6(1):65.2397-768Xhttp://hdl.handle.net/10668/19633The advent of dose intensified interval compressed therapy has improved event-free survival for patients with localized Ewing sarcoma (EwS) to 78% at 5 years. However, nearly a quarter of patients with localized tumors and 60-80% of patients with metastatic tumors suffer relapse and die of disease. In addition, those who survive are often left with debilitating late effects. Clinical features aside from stage have proven inadequate to meaningfully classify patients for risk-stratified therapy. Therefore, there is a critical need to develop approaches to risk stratify patients with EwS based on molecular features. Over the past decade, new technology has enabled the study of multiple molecular biomarkers in EwS. Preliminary evidence requiring validation supports copy number changes, and loss of function mutations in tumor suppressor genes as biomarkers of outcome in EwS. Initial studies of circulating tumor DNA demonstrated that diagnostic ctDNA burden and ctDNA clearance during induction are also associated with outcome. In addition, fusion partner should be a pre-requisite for enrollment on EwS clinical trials, and the fusion type and structure require further study to determine prognostic impact. These emerging biomarkers represent a new horizon in our understanding of disease risk and will enable future efforts to develop risk-adapted treatment.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Cancer geneticsMolecular medicinePrognostic markersSarcomaHumansPrognosisCirculating Tumor DNASarcoma, EwingDNA Copy Number VariationsLoss of Function MutationProgression-Free SurvivalDisease Progressionresearch article36115869open accessPacientesRiesgoBiomarcadoresTerapéuticaNeoplasiasEnfermedadPredicciónDosificaciónSupervivencia sin progresión10.1038/s41698-022-00307-2PMC9482616https://www.nature.com/articles/s41698-022-00307-2.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482616/pdf